Matthias Griese

List of Publications by Year in Descending Order

157 papers	6,667 citations	39 h-index	78 g-index
169 ext. papers	8,330 ext. citations	7 avg, IF	5.45 L-index

#	Paper	IF	Citations
157	Spezielle interstitielle Lungenerkrankungen im Kindesalter **2022**, 361-380		
156	Pulmonary alveolar proteinosis due to heterozygous mutation in OAS1: Whole lung lavages for long-term bridging to hematopoietic stem cell transplantation. *Pediatric Pulmonology*, **2022**, 57, 273-277	3.5	0
155	Incidence and Prevalence of Children Diffuse Lung Disease in Spain.. *Archivos De Bronconeumologia*, **2022**, 58, 22-29	0.7	1
154	Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease. *ERJ Open Research*, **2021**, 7,	3.5	1
153	Hypersensitivity pneumonitis: Lessons from a randomized controlled trial in children. *Pediatric Pulmonology*, **2021**, 56, 2627-2633	3.5	1
152	Heterozygous gain-of-function variants cause an autoinflammatory immunodeficiency. *Science Immunology*, **2021**, 6,	28	6
151	Expanding the phenotypic spectrum of FINCA (fibrosis, neurodegeneration, and cerebral angiomatosis) syndrome beyond infancy. *Clinical Genetics*, **2021**, 100, 453-461	4	3
150	Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 381-385	10.2	41
149	Comorbidity and long-term clinical outcome of laryngotracheal clefts types III and IV: Systematic analysis of new cases. *Pediatric Pulmonology*, **2021**, 56, 138-144	3.5	0
148	The Human Phenotype Ontology in 2021. *Nucleic Acids Research*, **2021**, 49, D1207-D1217	20.1	131
147	Surfactant dysfunction syndromes and pulmonary alveolar proteinosis **2021**, 602-609		
146	Airways glutathione S-transferase omega-1 and its A140D polymorphism are associated with severity of inflammation and respiratory dysfunction in cystic fibrosis. *Journal of Cystic Fibrosis*, **2021**, 20, 1053-1061	4.1	2
145	FARS1-related disorders caused by bi-allelic mutations in cytosolic phenylalanyl-tRNA synthetase genes: Look beyond the lungs!. *Clinical Genetics*, **2021**, 99, 789-801	4	2
144	Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis. *Frontiers in Pharmacology*, **2021**, 12, 577263	5.6	1
143	Multisystem inflammation and susceptibility to viral infections in human ZNFX1 deficiency. *Journal of Allergy and Clinical Immunology*, **2021**, 148, 381-393	11.5	10
142	The improved clinical course of persistent tachypnea of infancy with inhaled bronchodilators and corticosteroids. *Pediatric Pulmonology*, **2021**, 56, 3952-3959	3.5	0
141	Early-onset, fatal interstitial lung disease in STAT3 gain-of-function patients. *Pediatric Pulmonology*, **2021**, 56, 3934-3941	3.5	0

140	High-content Screen Identifies Cyclosporin A as a Novel ABCA3-specific Molecular Corrector.. *American Journal of Respiratory Cell and Molecular Biology*, **2021**,	5.7	2
139	Case Report: Unilateral Sixth Cranial Nerve Palsy Associated With COVID-19 in a 2-year-old Child.. *Frontiers in Pediatrics*, **2021**, 9, 756014	3.4	2
138	Treating Allergic Bronchopulmonary Aspergillosis with Short-Term Prednisone and Itraconazole in Cystic Fibrosis. *Journal of Allergy and Clinical Immunology: in Practice*, **2020**, 8, 2608-2614.e3	5.4	6
137	Variation in the bombesin staining of pulmonary neuroendocrine cells in pediatric pulmonary disorders-A useful marker for airway maturity. *Pediatric Pulmonology*, **2020**, 55, 2383-2388	3.5	4
136	Postinfectious Bronchiolitis Obliterans in Children: Diagnostic Workup and Therapeutic Options: A Workshop Report. *Canadian Respiratory Journal*, **2020**, 2020, 5852827	2.1	12
135	Lymphocytic interstitial pneumonia and follicular bronchiolitis in children: A registry-based case series. *Pediatric Pulmonology*, **2020**, 55, 909-917	3.5	8
134	Lung ultrasound-a new diagnostic modality in persistent tachypnea of infancy. *Pediatric Pulmonology*, **2020**, 55, 1028-1036	3.5	1
133	One-year outcomes in a multicentre cohort study of incident rare diffuse parenchymal lung disease in children (ChILD). *Thorax*, **2020**, 75, 172-175	7.3	4
132	Persistent tachypnea of infancy: Follow up at school age. *Pediatric Pulmonology*, **2020**, 55, 3119-3125	3.5	4
131	Pulmonary function testing in children interstitial lung disease. *European Respiratory Review*, **2020**, 29,	9.8	3
130	Rescue of respiratory failure in pulmonary alveolar proteinosis due to pathogenic MARS1 variants. *Pediatric Pulmonology*, **2020**, 55, 3057-3066	3.5	8
129	Prospective evaluation of hydroxychloroquine in pediatric interstitial lung diseases: Study protocol for an investigator-initiated, randomized controlled, parallel-group clinical trial. *Trials*, **2020**, 21, 307	2.8	3
128	Patient education for children with interstitial lung diseases and their caregivers: A pilot study. *Patient Education and Counseling*, **2019**, 102, 1131-1139	3.1	2
127	Potentiation of ABCA3 lipid transport function by ivacaftor and genistein. *Journal of Cellular and Molecular Medicine*, **2019**, 23, 5225-5234	5.6	16
126	Phenotype characterisation of mutation and deletion carriers with neonatal and paediatric pulmonary hypertension. *European Respiratory Journal*, **2019**, 54,	13.6	36
125	Quantitative Lipidomics in Pulmonary Alveolar Proteinosis. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 881-887	10.2	15
124	Lavage lipidomics signatures in children with cystic fibrosis and protracted bacterial bronchitis. *Journal of Cystic Fibrosis*, **2019**, 18, 790-795	4.1	9
123	Pulmonary alveolar proteinosis. *Nature Reviews Disease Primers*, **2019**, 5, 16	51.1	106

122	Lung disease in STAT3 hyper-IgE syndrome requires intense therapy. *Allergy: European Journal of Allergy and Clinical Immunology*, **2019**, 74, 1691-1702	9.3	8
121	Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF). *BMC Pulmonary Medicine*, **2019**, 19, 130	3.5	15
120	Metabolic labelling of choline phospholipids probes ABCA3 transport in lamellar bodies. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2019**, 1864, 158516	5	5
119	Bi-allelic missense mutations in a patient with childhood ILD who reached adulthood. *ERJ Open Research*, **2019**, 5,	3.5	9
118	Abandoning developmental silos: what can paediatricians and adult interstitial lung disease physicians learn from each other?. *Current Opinion in Pulmonary Medicine*, **2019**, 25, 418-425	3	1
117	Early onset children's interstitial lung diseases: Discrete entities or manifestations of pulmonary dysmaturity?. *Paediatric Respiratory Reviews*, **2019**, 30, 65-71	4.8	13
116	Development and validation of a health-related quality of life questionnaire for pediatric patients with interstitial lung disease. *Pediatric Pulmonology*, **2018**, 53, 954-963	3.5	12
115	Chronic interstitial lung disease in children. *European Respiratory Review*, **2018**, 27,	9.8	22
114	Functional rescue of misfolding ABCA3 mutations by small molecular correctors. *Human Molecular Genetics*, **2018**, 27, 943-953	5.6	22
113	Hermansky-Pudlak syndrome type 2 manifests with fibrosing lung disease early in childhood. *Orphanet Journal of Rare Diseases*, **2018**, 13, 42	4.2	22
112	ABCA3 missense mutations causing surfactant dysfunction disorders have distinct cellular phenotypes. *Human Mutation*, **2018**, 39, 841-850	4.7	19
111	Assessment of the multiplex PCR-based assay Unyvero pneumonia application for detection of bacterial pathogens and antibiotic´resistance genes in children and neonates. *Infection*, **2018**, 46, 189-196	5.8	25
110	International management platform for children's interstitial lung disease (chILD-EU). *Thorax*, **2018**, 73, 231-239	7.3	30
109	Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, 214-224	10.2	107
108	Bi-allelic Mutations in Phe-tRNA Synthetase Associated with a Multi-system Pulmonary Disease Support Non-translational Function. *American Journal of Human Genetics*, **2018**, 103, 100-114	11	20
107	Pathogenesis, imaging and clinical characteristics of CF and non-CF bronchiectasis. *BMC Pulmonary Medicine*, **2018**, 18, 79	3.5	24
106	Lung disease caused by mutations. *Thorax*, **2017**, 72, 213-220	7.3	74
105	Pott's disease: a major issue for an unaccompanied refugee minor. *Thorax*, **2017**, 72, 282-283	7.3	5

104	Increasing Total Serum IgE, Allergic Bronchopulmonary Aspergillosis, and Lung Function in Cystic Fibrosis. *Journal of Allergy and Clinical Immunology: in Practice*, **2017**, 5, 1591-1598.e6	5.4	8
103	Increasing sputum levels of gamma-glutamyltransferase may identify cystic fibrosis patients who do not benefit from inhaled glutathione. *Journal of Cystic Fibrosis*, **2017**, 16, 342-345	4.1	6
102	Quantification of volume and lipid filling of intracellular vesicles carrying the ABCA3 transporter. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2017**, 1864, 2330-2335	4.9	15
101	Pulmonary Alveolar Proteinosis: A Comprehensive Clinical Perspective. *Pediatrics*, **2017**, 140,	7.4	28
100	An informative intragenic microsatellite marker suggests the IL-1 receptor as a genetic modifier in cystic fibrosis. *European Respiratory Journal*, **2017**, 50,	13.6	6
99	Surfactant proteins in pediatric interstitial lung disease. *Pediatric Research*, **2016**, 79, 34-41	3.2	13
98	Delivery of Alpha-1 Antitrypsin to Airways. *Annals of the American Thoracic Society*, **2016**, 13 Suppl 4, S346-51	4.7	23
97	European idiopathic pulmonary fibrosis Patient Charter: a missed opportunity. *European Respiratory Journal*, **2016**, 48, 282-3	13.6	2
96	Homooligomerization of ABCA3 and its functional significance. *International Journal of Molecular Medicine*, **2016**, 38, 558-66	4.4	2
95	Persistent Tachypnea of Infancy. Usual and Aberrant. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 193, 438-47	10.2	31
94	Cardiovascular risk in pulmonary alveolar proteinosis. *Expert Review of Respiratory Medicine*, **2016**, 10, 235-40	3.8	1
93	Spezielle interstitielle Lungenerkrankungen im Kindesalter **2016**, 283-296		
92	Increased Risk of Interstitial Lung Disease in Children with a Single R288K Variant of ABCA3. *Molecular Medicine*, **2016**, 22, 183-191	6.2	14
91	Analysis of the Proteolytic Processing of ABCA3: Identification of Cleavage Site and Involved Proteases. *PLoS ONE*, **2016**, 11, e0152594	3.7	7
90	Serum Levels of Surfactant Proteins in Patients with Combined Pulmonary Fibrosis and Emphysema (CPFE). *PLoS ONE*, **2016**, 11, e0157789	3.7	10
89	A Global Survey on Whole Lung Lavage in Pulmonary Alveolar Proteinosis. *Chest*, **2016**, 150, 251-3	5.3	12
88	Adherence pattern to study drugs in clinical trials by patients with cystic fibrosis. *Pediatric Pulmonology*, **2016**, 51, 143-6	3.5	7
87	Tools to explore ABCA3 mutations causing interstitial lung disease. *Pediatric Pulmonology*, **2016**, 51, 1284-1294	3.5	15

86	Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures. *Orphanet Journal of Rare Diseases*, **2016**, 11, 115	4.2	62
85	Microbial colonization and lung function in adolescents with cystic fibrosis. *Journal of Cystic Fibrosis* , **2016**, 15, 340-9	4.1	39
84	Chitinase activation in patients with fungus-associated cystic fibrosis lung disease. *Journal of Allergy and Clinical Immunology*, **2016**, 138, 1183-1189.e4	11.5	25
83	European protocols for the diagnosis and initial treatment of interstitial lung disease in children. *Thorax*, **2015**, 70, 1078-84	7.3	113
82	Pulmonary alveolar proteinosis: time to shift?. *Expert Review of Respiratory Medicine*, **2015**, 9, 337-49	3.8	14
81	ABCA3 protects alveolar epithelial cells against free cholesterol induced cell death. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2015**, 1851, 987-95	5	14
80	Biallelic Mutations of Methionyl-tRNA Synthetase Cause a Specific Type of Pulmonary Alveolar Proteinosis Prevalent on R□nion Island. *American Journal of Human Genetics*, **2015**, 96, 826-31	11	71
79	GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders. *BMC Pulmonary Medicine*, **2015**, 15, 87	3.5	48
78	CXCR4+ granulocytes reflect fungal cystic fibrosis lung disease. *European Respiratory Journal*, **2015**, 46, 395-404	13.6	8
77	Genotype alone does not predict the clinical course of SFTPC deficiency in paediatric patients. *European Respiratory Journal*, **2015**, 46, 197-206	13.6	44
76	Respiratory Bronchiolitis-Associated Interstitial Lung Disease in Childhood: New Sequela of Smoking. *Pediatrics*, **2015**, 136, e1026-9	7.4	2
75	Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases. *Pediatric Pulmonology*, **2015**, 50, 410-9	3.5	30
74	Categorizing diffuse parenchymal lung disease in children. *Orphanet Journal of Rare Diseases*, **2015**, 10, 122	4.2	27
73	Pulmonary alveolar proteinosis in a cat. *BMC Veterinary Research*, **2015**, 11, 302	2.7	5
72	Life-threatening, giant pneumatoceles in the course of surfactant protein C deficiency. *Pediatric Pulmonology*, **2015**, 50, E25-8	3.5	4
71	Free DNA in cystic fibrosis airway fluids correlates with airflow obstruction. *Mediators of Inflammation*, **2015**, 2015, 408935	4.3	65
70	Surfactant lipidomics in healthy children and childhood interstitial lung disease. *PLoS ONE*, **2015**, 10, e0117985	3.7	32
69	In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency. *Nature Biotechnology*, **2015**, 33, 584-6	44.5	97

68	Mutations in CCNO result in congenital mucociliary clearance disorder with reduced generation of multiple motile cilia. *Nature Genetics*, **2014**, 46, 646-51	36.3	166
67	Predictive values of antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis one year after early eradication treatment. *Journal of Cystic Fibrosis*, **2014**, 13, 534-41	4.1	7
66	Pulmonary alveolar proteinosis in children on La Réunion Island: a new inherited disorder?. *Orphanet Journal of Rare Diseases*, **2014**, 9, 85	4.2	23
65	A large kindred of pulmonary fibrosis associated with a novel ABCA3 gene variant. *Respiratory Research*, **2014**, 15, 43	7.3	75
64	Long-term inhaled granulocyte macrophage-colony-stimulating factor in autoimmune pulmonary alveolar proteinosis: effectiveness, safety, and lowest effective dose. *Clinical Drug Investigation*, **2014**, 34, 553-64	3.2	20
63	Comprehensive genotyping and clinical characterisation reveal 27 novel NKX2-1 mutations and expand the phenotypic spectrum. *Journal of Medical Genetics*, **2014**, 51, 375-87	5.8	60
62	The chemokine CCL18 characterises Pseudomonas infections in cystic fibrosis lung disease. *European Respiratory Journal*, **2014**, 44, 1608-15	13.6	12
61	Characterization of CSF2RA mutation related juvenile pulmonary alveolar proteinosis. *Orphanet Journal of Rare Diseases*, **2014**, 9, 171	4.2	41
60	Successful weaning from mechanical ventilation in a patient with surfactant protein C deficiency presenting with severe neonatal respiratory distress. *BMJ Case Reports*, **2014**, 2014,	0.9	9
59	Sonstige Lungenerkrankungen **2014**, 773-786		
58	Zystische Fibrose **2014**, 795-818		
57	Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 83-9	10.2	66
56	Hypersensitivity pneumonitis: lessons for diagnosis and treatment of a rare entity in children. *Orphanet Journal of Rare Diseases*, **2013**, 8, 121	4.2	30
55	The basidiomycetous yeast Trichosporon may cause severe lung exacerbation in cystic fibrosis patients - clinical analysis of Trichosporon positive patients in a Munich cohort. *BMC Pulmonary Medicine*, **2013**, 13, 61	3.5	18
54	Research in progress: put the orphanage out of business. *Thorax*, **2013**, 68, 971-3	7.3	19
53	SFTPC mutations cause SP-C degradation and aggregate formation without increasing ER stress. *European Journal of Clinical Investigation*, **2013**, 43, 791-800	4.6	24
52	The risk of hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type 2. *Blood*, **2013**, 121, 2943-51	2.2	60
51	The surfactant protein C mutation A116D alters cellular processing, stress tolerance, surfactant lipid composition, and immune cell activation. *BMC Pulmonary Medicine*, **2012**, 12, 15	3.5	19

50	Wash-out kinetics and efficacy of a modified lavage technique for alveolar proteinosis. *European Respiratory Journal*, **2012**, 40, 1468-74	13.6	21
49	Respiratory syncytial virus potentiates ABCA3 mutation-induced loss of lung epithelial cell differentiation. *Human Molecular Genetics*, **2012**, 21, 2793-806	5.6	31
48	Surfactant protein a in cystic fibrosis: supratrimeric structure and pulmonary outcome. *PLoS ONE*, **2012**, 7, e51050	3.7	5
47	Pulmonary alveolar proteinosis: new insights from a single-center cohort of 70 patients. *Respiratory Medicine*, **2011**, 105, 1908-16	4.6	75
46	Pulmonary hypertension presenting with apnea, cyanosis, and failure to thrive in a young child. *Chest*, **2011**, 140, 1086-1089	5.3	1
45	Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. *Nature Biotechnology*, **2011**, 29, 154-7	44.5	498
44	Long-term follow-up and treatment of congenital alveolar proteinosis. *BMC Pediatrics*, **2011**, 11, 72	2.6	29
43	Some ABCA3 mutations elevate ER stress and initiate apoptosis of lung epithelial cells. *Respiratory Research*, **2011**, 12, 4	7.3	70
42	Fatal neonatal respiratory failure in an infant with congenital hypothyroidism due to haploinsufficiency of the NKX2-1 gene: alteration of pulmonary surfactant homeostasis. *Archives of Disease in Childhood: Fetal and Neonatal Edition*, **2011**, 96, F453-6	4.7	31
41	A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *New England Journal of Medicine*, **2011**, 365, 1663-72	59.2	1465
40	Whole-lung lavage in infants and children with pulmonary alveolar proteinosis. *Paediatric Anaesthesia*, **2010**, 20, 1118-23	1.8	26
39	Expression, regulation and clinical significance of soluble and membrane CD14 receptors in pediatric inflammatory lung diseases. *Respiratory Research*, **2010**, 11, 32	7.3	33
38	The surfactant lipid transporter ABCA3 is N-terminally cleaved inside LAMP3-positive vesicles. *FEBS Letters*, **2010**, 584, 4306-12	3.8	27
37	A non-BRICHOS surfactant protein c mutation disrupts epithelial cell function and intercellular signaling. *BMC Cell Biology*, **2010**, 11, 88		17
36	Assessment of surfactant protein A (SP-A) dependent agglutination. *BMC Pulmonary Medicine*, **2010** , 10, 59	3.5	5
35	Meconium ileus-it is time to act now!. *Pediatric Pulmonology*, **2010**, 45, 949-50	3.5	1
34	Long-term pulmonary outcome after meconium ileus in cystic fibrosis. *Pediatric Pulmonology*, **2009**, 44, 1201-6	3.5	19
33	Incidence and classification of pediatric diffuse parenchymal lung diseases in Germany. *Orphanet Journal of Rare Diseases*, **2009**, 4, 26	4.2	70

32	TLR expression on neutrophils at the pulmonary site of infection: TLR1/TLR2-mediated up-regulation of TLR5 expression in cystic fibrosis lung disease. *Journal of Immunology*, **2008**, 181, 2753-63	5.3	79
31	Surfactant proteins SP-B and SP-C and their precursors in bronchoalveolar lavages from children with acute and chronic inflammatory airway disease. *BMC Pulmonary Medicine*, **2008**, 8, 6	3.5	23
30	Deleted in Malignant Brain Tumors 1 (DMBT1) is present in hyaline membranes and modulates surface tension of surfactant. *Respiratory Research*, **2007**, 8, 69	7.3	12
29	Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. *Nature Medicine*, **2007**, 13, 1423-30	50.5	245
28	Oxidative changes of bronchoalveolar proteins in cystic fibrosis. *Chest*, **2006**, 129, 431-437	5.3	54
27	Alteration of the pulmonary surfactant system in full-term infants with hereditary ABCA3 deficiency. *American Journal of Respiratory and Critical Care Medicine*, **2006**, 174, 571-80	10.2	124
26	Oxidative damage to surfactant protein D in pulmonary diseases. *Free Radical Research*, **2006**, 40, 419-25	4	26
25	Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. *Journal of Allergy and Clinical Immunology*, **2006**, 117, 204-11	11.5	153
24	Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients. *Respiratory Research*, **2005**, 6, 133	7.3	24
23	Therapeutic lung lavages in children and adults. *Respiratory Research*, **2005**, 6, 138	7.3	20
22	Interstitial lung disease in children -- genetic background and associated phenotypes. *Respiratory Research*, **2005**, 6, 32	7.3	39
21	Expression profiles of hydrophobic surfactant proteins in children with diffuse chronic lung disease. *Respiratory Research*, **2005**, 6, 80	7.3	19
20	Skin prick test reactivity to supplemental enzymes in cystic fibrosis and pancreatic insufficiency. *Journal of Pediatric Gastroenterology and Nutrition*, **2005**, 40, 194-8	2.8	5
19	Agglutination of Pseudomonas aeruginosa by surfactant protein D. *Pediatric Pulmonology*, **2005**, 40, 378-84	3.5	11
18	Pulmonary surfactant, lung function, and endobronchial inflammation in cystic fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 170, 1000-5	10.2	62
17	Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 169, 822-8	10.2	96
16	Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 169, 719-25	10.2	135
15	Cytokine stimulation by Pseudomonas aeruginosa--strain variation and modulation by pulmonary surfactant. *Experimental Lung Research*, **2004**, 30, 163-79	2.3	12

14	Exhaled breath condensate. *Pediatric Pulmonology*, **2004**, 26, 14-5	3.5	2
13	Mutation of SFTPC in infantile pulmonary alveolar proteinosis with or without fibrosing lung disease. *American Journal of Medical Genetics Part A*, **2004**, 126A, 18-26		96
12	Surfactant protein A and D differently regulate the immune response to nonmucoid Pseudomonas aeruginosa and its lipopolysaccharide. *American Journal of Respiratory Cell and Molecular Biology*, **2003**, 28, 249-56	5.7	80
11	Analysis of 40 sporadic or familial neonatal and pediatric cases with severe unexplained respiratory distress: relationship to SFTPB. *American Journal of Medical Genetics Part A*, **2003**, 119A, 324-39		44
10	Elemental and ion composition of exhaled air condensate in cystic fibrosis. *Journal of Cystic Fibrosis*, **2003**, 2, 136-42	4.1	19
9	Protein pattern of exhaled breath condensate and saliva. *Proteomics*, **2002**, 2, 690-6	4.8	66
8	Respiratory syncytial virus and pulmonary surfactant. *Viral Immunology*, **2002**, 15, 357-63	1.7	37
7	Surfactant proteins A and D in children with pulmonary disease due to gastroesophageal reflux. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 165, 1546-50	10.2	50
6	Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis. *European Journal of Medical Research*, **2002**, 7, 79-80	4.8	31
5	Reduced proteolysis of surfactant protein A and changes of the bronchoalveolar lavage fluid proteome by inhaled alpha 1-protease inhibitor in cystic fibrosis. *Electrophoresis*, **2001**, 22, 165-71	3.6	45
4	Uptake of a natural surfactant and increased delivery of small organic anions into type II pneumocytes. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2001**, 281, L144-54	5.8	2
3	Pulmonary complications after bone marrow transplantation in children: twenty-four years of experience in a single pediatric center. *Pediatric Pulmonology*, **2000**, 30, 393-401	3.5	117
2	Compound SFTPB 1549C-->GAA (121ins2) and 457delC heterozygosity in severe congenital lung disease and surfactant protein B (SP-B) deficiency. *Human Mutation*, **1999**, 14, 502-9	4.7	38
1	Cibacron blue stimulation of surfactant secretion in rat type II pneumocytes. *British Journal of Pharmacology*, **1992**, 106, 373-9	8.6	2